MUG ChoSa1: A novel human chondrosarcoma model for preclinical evaluation of chemotherapeutics and carbon ion radiotherapy
Dedifferentiated chondrosarcoma is an aggressive bone malignancy characterised by intrinsic resistance to chemotherapy and radiotherapy, highlighting the need for representative preclinical models and novel therapeutic strategies. We established MUG ChoSa1, a patient-derived dedifferentiated chondrosarcoma cell line harbouring an IDH1 p.R132C mutation, and investigated its molecular response to carbon ion irradiation (C-ion IR), Doxorubicin, Lurbinectedin, and combination treatment. MUG ChoSa1 retained key morphological characteristics of the primary tumour, demonstrated stable in vitro growth and formed subcutaneous tumours in two NRG nude mice, providing preliminary evidence of its tumorigenic potential. C-ion IR induced dose-dependent G 2 /M arrest and rapid activation of the DNA damage response (DDR), including phosphorylation of ATM, ATR, CHK1/2, DNA-PKcs, and p53, with γH2AX induction but minimal apoptosis. Transcriptomic profiling identified 6852 differentially expressed genes after C-ion IR, characterised by downregulation of cell cycle regulators and enrichment of DNA repair, replication, checkpoint, and immune pathways. Both Doxorubicin and Lurbinectedin reduced cell viability, although Doxorubicin induced earlier and stronger apoptosis. RNA sequencing revealed distinct treatment-specific transcriptional programs, with Lurbinectedin preferentially regulating DNA repair, replication, and cell cycle pathways, whereas Doxorubicin predominantly activated stress-associated pathways. Combined Lurbinectedin and C-ion IR was associated with more pronounced transcriptional changes in DNA repair and replication-related programs, whereas Doxorubicin plus IR elicited a comparatively less extensive transcriptional response. RT-qPCR and immunoblotting supported treatment-associated alterations in DDR signalling. MUG ChoSa1 represents a clinically relevant model for dedifferentiated chondrosarcoma and demonstrates that C-ion IR induces a predominantly checkpoint- and repair-driven response that is differentially modulated by Doxorubicin and Lurbinectedin. These findings provide a molecular basis of further investigation of combination strategies involving C-ion IR, although their therapeutic efficacy remains to be established.
Authors
- Beate Rinner (ORCID: https://orcid.org/0000-0002-6340-4905)
- Liegl-Atzwanger Bernadette
- Christina Karner (ORCID: https://orcid.org/0000-0001-7088-3046)
- Dietmar Glänzer
- Joanna Szkandera (ORCID: https://orcid.org/0000-0002-2217-893X)
- Sachin Gadakh (ORCID: https://orcid.org/0000-0002-7524-7898)
- Birgit Lohberger (ORCID: https://orcid.org/0000-0002-3156-7902)
- Monika Staniszewska (ORCID: https://orcid.org/0000-0002-6271-3482)
- Djenana Vejzović (ORCID: https://orcid.org/0000-0002-7526-4399)
- Christian Viertler (ORCID: https://orcid.org/0000-0003-3729-2900)
- Teresa Szczepińska (ORCID: https://orcid.org/0000-0001-9749-1253)
- Richard Mate
Institutions
- Warsaw University of Technology (PL)
- University of Graz (AT)
- Medical University of Graz (AT)
- BioTechMed-Graz (AT)
Publication Details
- Journal
- Biomedicine & Pharmacotherapy
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1016/j.biopha.2026.120047
- Primary Topic
- Bone Tumor Diagnosis and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00